MHRA Safety Interactive Drug Analysis Profile - Oxymetazoline Hydrochloride

[Guide]

David Pascoe wrote a post about how the United Kingdom Medicines and Healthcare Regulatory Agency (MHRA) has issued a Drug Safety Interactive Drug Analysis Profile for the topical treatment Mirvaso, using the Yellow Card Scheme and also mentioned Rhofade (Oxymetazoline Hydrochloride). You can read the Interactive Drug Analysis Profile with the suspected Adverse Drug Reactions (ADRs) reported through the Yellow Card Scheme which include adverse side effects such as cardiac disorders, among many other reported symptoms from users. David also mentions a report that concludes that oxymetazoline may cause drug-induced valvulopathy, a heart disorder. [1]

UK residents can now receive news updates from the MHRA and report side effects to medicines via the Yellow Card app.
You will need to create a separate account on the app to report and download it from the Apple App Store, or Google Play Store.

USA residents can report adverse effects using Mirvaso to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch or fill out an online report. 

End Notes

[1] Warning About Using Rhofade With Cardiovascular Disease